Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, July 21, 2026, 11:00-11:30 AM CT

Learning Objectives:
  • Explain how transparency and manufacturer partnerships improve quality, consistency, and decision-making confidence in specimen management.
  • Evaluate blood collection tubes beyond cost and commodity assumptions, incorporating clinical impact and risk into decision-making.
  • Assess the potential risk points when using a blood collection device that has not been cleared for a specific purpose.

Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Abstracts

Clinical pathology selected abstracts

June 2025—Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist medication that has FDA approval for treating diabetes and obesity and that has shown exceptional efficacy. A rapid increase in use of this drug has been accompanied by reports of reduced alcohol use and cravings during semaglutide treatment. Alcohol use is a leading modifiable cause of morbidity and mortality and accounts for four to five percent of disease burden and 2.6 million deaths per year globally. Alcohol is also associated with increased risk of common diseases, including cardiovascular and liver disease and cancers. It is estimated that approximately 29 and 11 percent of U.S. adults meet lifetime and past-year criteria for alcohol use disorder (AUD), respectively.

Anatomic pathology selected abstracts

June 2025—Transbronchial cryobiopsies are increasingly used to diagnose interstitial lung disease, but published information on the features of specific manifestations of ILD in cryobiopsies is lacking. Therefore, the authors sought to provide pathologic guidelines for separating usual interstitial pneumonia (UIP) of idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (FHP), and connective tissue disease-associated interstitial lung disease (CTD-ILD) in cryobiopsies. They examined 120 cryobiopsies from patients with CTD-ILD established via multidisciplinary discussion and compared them with a prior series of 121 biopsies from patients with IPF or FHP also established via multidisciplinary discussion. A nonspecific interstitial pneumonia (NSIP) pattern alone was seen in 36 of 120 (30 percent) CTD-ILD, three of 83 (3.6 percent) FHP, and two of 38 (5.2 percent) IPF cases, statistically favoring a diagnosis of CTD-ILD.

Molecular pathology selected abstracts

June 2025—Comprehensive molecular profiling and DNA methylation classification have become critical for diagnosing and managing central nervous system tumors. However, workflows for molecular testing of these tumors are often limited by the cost of equipment and reagents, technical complexity, and lengthy turnaround times. The wide range of alterations that can be present, including MGMT promoter methylation, single nucleotide variants, insertions or deletions (indels), copy number variants, and fusions and structural variants, often necessitate the use of multiple assays for a complete molecular workup. All of these factors have led to a growing demand for molecular assays that are faster, more comprehensive, and more accessible. Recognizing this need, the authors had previously conducted a proof-of-concept study of an adaptive sampling-based nanopore sequencing workflow platform, called Rapid-CNS2, that they had developed.

Clinical pathology selected abstracts

May 2025—Independent risk factors for many cancers include health conditions such as type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLA-1RAs) are an effective treatment for these chronic conditions and provide glycemic control, weight reduction, and immunomodulation. In a recent study, GLP-1RAs were associated with lower cancer risk in solid tumor cancers. However, the relationship between GLP-1RAs and hematological cancers has not been explored. Therefore, the authors conducted a study to compare the risk of hematological cancers in patients with type 2 diabetes treated with GLP-1RAs to that of patients with type 2 diabetes treated with metformin or insulin. The primary outcome was a first diagnosis of a hematological cancer within 15 years of an antidiabetic drug being prescribed. The retrospective cohort study used TriNetX, a repository of aggregated electronic health record data of medical encounters for approximately 25 percent of the U.S. population. The platform includes medical information from various age groups, racial and ethnic backgrounds, income levels, and insurance types.

Anatomic pathology selected abstracts

May 2025—Many pancreatic neuroendocrine tumors fall into two major prognostic subtypes based on DAXX/ATRX-induced alternative lengthening of the telomerase phenotype and alpha- and beta-cell-like epigenomic profiles. However, some do not fit into either subtype. Furthermore, despite advanced genotyping, pancreatic neuroendocrine tumors (PanNET) are generally not well characterized in terms of their histologic and hormonal phenotypes. The authors conducted a study to identify new subgroups of PanNET by extending transcription factor signatures and investigating their correlation with histologic, hormonal, molecular, and prognostic findings. One hundred eighty-five PanNET (165 nonfunctioning and 20 functioning), resected between 1996 and 2023, were classified into the subgroups A1, A2, B, C, and D.

Molecular pathology selected abstracts

May 2025—As genomic technology and scientific knowledge advance, so too do their applications in health care. Clinical genetic testing, preimplantation genetic diagnosis (PGD), and heritable human genome editing (HHGE) are an ever-growing and evolving part of genomic medicine. The author explored the significance of lived experiences with genetic disease relative to understanding the severity or seriousness of such diseases in the genomic age. She focused on severity of disease, perceptions of symptoms of disease or associations with disease, and interplay between symptoms of disease and associations with disease. The data presented were collected as part of a larger mixed-methods research project exploring factors that influence attitudes toward the use of HHGE as a potential reproductive choice in the United Kingdom and how identifying those factors could aid the design of future regulations.

Clinical pathology selected abstracts

April 2025—Regulatory requirements in title 45, section 164.524 of the Code of Federal Regulations state that covered entities must provide patients or their designated representatives with patient health care records upon request. This is true for all laboratory testing, including such complex texting as next-generation sequencing (NGS). The protected health information that can be requested includes billing and payment records and clinic notes. Exceptions to the requirement to provide protected health information are very limited. However, questions arise with regard to complex laboratory testing, such as what information related to genomic testing should be included in the data set and what should be taken into consideration for the release and receipt of this information.

Anatomic pathology selected abstracts

April 2025—Claudin-18.2 (CLDN18.2) is a biomarker for locally advanced or metastatic gastric and gastroesophageal junction adenocarcinomas that may respond to targeted therapy with monoclonal antibodies directed against CLDN18.2. Despite successful testing in clinical trials, no practical testing guidelines had been proposed at the time the authors’ article featured herein was published. Several preanalytical and analytical variables may interfere with CLDN18.2 staining interpretation. Therefore, the authors provided practical guidance on CLDN18.2 testing and scoring in gastric and gastroesophageal junction adenocarcinomas. They established criteria pertaining to sample characteristics, analytical requirements, staining evaluation, and reporting.

Pathology informatics selected abstracts

April 2025—Hirschsprung disease is characterized by the absence of ganglion cells in the intestinal wall. Determining whether ganglion cells are present in an effort to identify Hirschsprung disease is a cumbersome task for pathologists that may require frozen section analysis; histopathologic assessment of a rectal biopsy specimen (the gold standard); use of special stains, such as AChE; IHC analysis of calretinin or S100; or molecular and genetic testing. To assist pathologists with evaluating challenging frozen sections, the authors developed an artificial intelligence (AI) solution designed to enhance the detection of ganglion cells during intraoperative consultation. The AI model was trained using a mixed data set that combined 366 frozen section and 302 formalin-fixed, paraffin-embedded H&E-stained slides procured from 164 patients across three medical centers in Turkey. After scanning the slides, pathologists helped train the deep learning model by annotating ganglion cells present in the whole slide images (WSI).

Molecular pathology selected abstracts

April 2025—Chronic kidney disease is more common in people of African ancestry, with Americans of African descent having four times the risk compared with Americans of European descent. This disparity is largely due to the G1 and G2 genetic variants in the APOL1 gene, which increase the risk of developing chronic kidney disease (CKD) when inherited in a homozygous or compound heterozygous pattern. These variants, exclusive to African populations, likely evolved over 10,000 years ago due to their protective role against African sleeping sickness. The prevalence of these variants varies across sub-Saharan Africa, and data on their connection to CKD in African populations are limited.

MARKETPLACE

TRENDING